6,759 Shares in Medpace Holdings, Inc. $MEDP Acquired by Inspire Investing LLC

Key Points

• Inspire Investing LLC has invested approximately $2.06 million in Medpace Holdings, acquiring 6,759 shares in the first quarter.
• Institutional investors collectively own 77.98% of Medpace, with several firms increasing their holdings significantly during the same period.
• Analyst ratings for Medpace are mixed, with two "Buy" ratings, eleven "Hold" ratings, and three "Sell" ratings, reflecting diverse perspectives on its stock performance.

Inspire Investing LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 6,759 shares of the company's stock, valued at approximately $2,059,000.

Several other hedge funds have also bought and sold shares of the company. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group lifted its holdings in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares during the last quarter. Whittier Trust Co. boosted its position in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Medpace in the first quarter valued at $60,000. Finally, Assetmark Inc. raised its position in shares of Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after purchasing an additional 43 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In related news, VP Susan E. Burwig sold 10,000 shares of the firm's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president owned 57,500 shares of the company's stock, valued at $27,600,000. This trade represents a 14.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. This represents a 66.67% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on MEDP shares. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and raised their price objective for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Cowen cut Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Rothschild & Co Redburn lowered Medpace from a "buy" rating to a "neutral" rating and upped their price objective for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Truist Financial increased their price objective on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Finally, William Blair reissued a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Reduce" and an average price target of $422.27.

Medpace Price Performance

Shares of MEDP stock traded up $4.98 on Thursday, hitting $502.81. 79,233 shares of the company's stock were exchanged, compared to its average volume of 438,442. The company has a 50 day moving average of $439.91 and a 200 day moving average of $352.60. The stock has a market cap of $14.12 billion, a P/E ratio of 37.36, a price-to-earnings-growth ratio of 3.09 and a beta of 1.44. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same quarter in the previous year, the firm earned $2.75 earnings per share. The business's quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.